Caxton Associates (New York)’s Atara Biotherapeutics ATRA Stock Holding History

Caxton Associates (New York)’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,246	Closed	-$90.4K	–	405
2023 Q2	$90.4K	Sell	2,246 -1,973	-47%	-$112K	0.01%	454
2023 Q1	$306K	Sell	4,219 -3,768	-47%	-$365K	0.05%	353
2022 Q4	$655K	Buy	7,987 +106	+1%	+$11K	0.04%	189
2022 Q3	$745K	Buy	7,881 +7,383	+1,483%	+$829K	0.1%	170
2022 Q2	$97K	Buy	+498	New	+$81.3K	0.01%	514

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caxton Associates (New York)'s ATRA Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Atara Biotherapeutics (ATRA) in Q3 2023, closing a stake of 2,246 shares — an estimated $90.4K sold.

Caxton Associates (New York) first reported a position in ATRA in Q2 2022 and held it in 5 quarters. The position peaked at $745K in Q3 2022. 109 funds tracked by Wall St. Rank hold ATRA as of Q3 2023.

Caxton Associates (New York) reported no remaining Atara Biotherapeutics position as of Q3 2023 after selling out during the quarter.
Caxton Associates (New York) sold 2,246 Atara Biotherapeutics shares in Q3 2023, an estimated $90.4K.
Caxton Associates (New York) first reported a position in Atara Biotherapeutics in Q2 2022 and held it in 5 quarters.
Caxton Associates (New York)'s Atara Biotherapeutics position peaked at $745K in Q3 2022.
109 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.